an open-label phase iii study of arfolitixorin vs ... · an open-label phase iii study of...
TRANSCRIPT
An open-label Phase III study of arfolitixorin vs leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer Heinz-Josef Lenz,1 Peter Gibbs,2 Sebastian Stintzing,3 Volker Heinemann,4 Gerald W. Prager,5 Peter Nygren,6 Christos A. Papadimitriou,7 Roger Tell,8 Takayuki Yoshino,9 Derek J. Jonker,10 Aimery de Gramont,11 Josep Tabernero12
1University of Southern California, Los Angeles, CA, USA; 2Western Health, Melbourne, Australia; 3Charité – Universitätsmedizin Berlin, Berlin, Germany; 4Klinikum der Universität München, München, Germany; 5Medical University of Vienna, Vienna, Austria; 6Uppsala University, Uppsala, Sweden; 7Aretaieion Hospital, Athens, Greece; 8Isofol Medical AB, Gothenburg, Sweden; 9National Cancer Center Hospital East, Chiba, Japan; 10Ottawa Hospital Research Institute, Ottawa, ON, Canada; 11Franco-British Hospital, Levallois-Perret, France; 12Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain
BACKGROUNDCurrent treatments and folate-based strategies• First-line treatment of metastatic colorectal cancer (mCRC) is typically with cytotoxic chemotherapy, combined with biologics such as bevacizumab,
cetuximab, or panitumumab1 • 5-fluorouracil(5-FU),co-administeredwiththefolateleucovorin,isanestablishedcornerstoneofmCRCtreatment.15-FUundergoesmetabolictransformation
to5-fluorodeoxyuridinemonophosphate(FdUMP),whichpotentlyinhibitsthethymidylatesynthaseenzyme,inturndisruptingDNAsynthesisandrepair, and resulting in cell death in rapidly proliferating tumor cells (Figure 1)2
• Foreffective5-FUinhibitionofthymidylatesynthase,folatesareco-administeredtoformastableternarycomplexofFdUMP,[6R]-5,10-methylenetetrahydrofolate(MTHF),andthymidylatesynthase3
• AllfolatescurrentlyapprovedforclinicaluseinpatientswithmCRCareprodrugsthatneedtobemetabolicallyactivatedto[6R]-MTHF,theactivethymidylatesynthasecofactorthatpotentiatestheeffectof5-FU(Figure 2)4
Mechanism of action of arfolitixorin• Arfolitixorinconsistsoftheactivecofactor[6R]-MTHFandthereforedoesnotrequiremulti-stepmetabolicactivation4 • Responseto5-FU/leucovorinmaybeimpairedbylowexpressionoffolate-activatinggenesduetoinsufficientlevelsofcofactorand,consequently,
weak inhibition of thymidylate synthase5,6
• Excess[6R]-MTHF,however,favorscompetitionatthethymidylatesynthasebindingsiteforFdUMPoverdeoxyuridinemonophosphate(dUMP), potentiallypermittingmoreextensiveandprolongedenzymeinhibitionfollowing5-FUtreatment(Figure 1)4
Arfolitixorin clinical data• InthePhaseI/IIpharmacokineticsstudyISO-CC-002,considerablyhigherintratumoralandintramucosalconcentrationsof[6R]-MTHFwereachievedin
patientsreceivingasingleintravenousdoseofarfolitixorincomparedwithlevoleucovorin,ateitheroftwoequimolardoselevels,whichisconsistentwith thepotentialforgreaterefficacyofarfolitixorin7
• PreliminarydatafromthePhaseI/IIstudyISO-CC-005,whichevaluatedtheefficacyofarfolitixorin/5-FU,aloneorincombinationwithirinotecan oroxaliplatin,andwithorwithoutbevacizumab,reportedearlytumorshrinkagein47%offirst-linepatientsafter8weeks.8Afterupto32weeks offollow-up,preliminaryoverallresponserate(ORR)wasachievedin58%ofpatients.8Themostfrequentlyreportedadverseeventsweretypicalchemotherapysideeffects,includingfatigue,nausea,neutropenia,diarrhea,vomiting,andneuropathy9
Phase III evaluation of arfolitixorin• EvaluationofarfolitixorininalargerrandomizedPhaseIIIclinicalsettingisrequiredtovalidateandextendthesedata
STUDY COUNTRIESTheAGENTstudywilltakeplace acrossmorethan100sitesin the following countries (Figure 4):
• Australia
• Austria
• Canada
• France
• Germany
• Greece
• Japan
• Spain
• Sweden
• USA
STUDY DATESKey study milestones (Figure 5):
• Firstpatientin:December18,2018
• Interimanalysis:Q32020
• FinalPFSdata:Q32021
• FinalOSdata:TBD
STUDY RATIONALE• It is hypothesized that the administration of arfolitixorin
will result in higher intracellular concentrations of the activethymidylatesynthasecofactor[6R]-MTHFinallpatients compared with leucovorin administration, with less inter- and intra-individual variability
• Inturn,thismaytranslatetoimprovedclinicalefficacyin5-FUtreatmentofmCRC
STUDY DESIGN• Thisisarandomized,multicenter,parallel-group,PhaseIIIstudyAGENT(NCT03750786)
tocomparetheefficacyofarfolitixorinrelativetothatofleucovorininpatientswithmCRCtreatedwith5-FU,oxaliplatin,andbevacizumab10
• Patientswillberandomizedina1:1ratiotoeithertheinvestigationalarm(arfolitixorin +5-FU+oxaliplatin[ARFOX]+bevacizumab)orthecomparatorarm(leucovorin+5-FU +oxaliplatin[modifiedFOLFOX-6]+bevacizumab),andtreateduntiloccurrenceofdiseaseprogressionbasedonResponseEvaluationCriteriainSolidTumors1.1criteria(Figure 3) or unacceptable toxicity
Key inclusion and exclusion criteria are listed in Table 1.
Contact: Professor Heinz-Josef Lenz, email: [email protected] Acknowledgements: This study is funded by Isofol Medical AB (publ). Medical writing assistance was provided by Shelley Morris of Syneos Health, UK, and funded by Isofol Medical AB (publ).
Table 1. Key eligibility criteria
PATIENTS• Targetrecruitmentincludesrandomizationof
440patientsin18monthsandiscurrentlyongoing (Figure 4).Anadaptivestudydesign,intendedtoensuresufficientstatisticalpowerwhileminimizingpatient numbers, includes the possibility to increase thesamplesizeto660patients,asdeterminedby theDataandSafetyMonitoringBoardduringtheinterimanalysistobecarriedoutafter330patients haveundergonetheir16-weekscan(Figure 3)
STUDY ENDPOINTS• TheprimarystudyendpointwillbeORRbyblindedindependentcentralreview,
definedasthebestresponsefromthestarttotheendofstudytreatment(Figure 3) • Keysecondaryendpointswillincludeprogression-freesurvival(PFS),definedastime
fromrandomizationtofirstoccurrenceoftumorprogressionbasedoncomputerizedtomographyscans/magneticresonanceimagingordeath,anddurationofresponse (DoR),measuredfromwhenmeasurementcriteriaarefirstmetforcompleteresponse/partialresponseuntilprogressivediseaseisfirstobjectivelydocumented
• Additionalsecondaryendpointsincludeoverallsurvival(OS),qualityoflife,safety and tolerability, and patients undergoing curative metastasis resection
REFERENCES1.VanCutsemE,etal.AnnOncol2016;27:1386–422;2.KlineCLB,etal.Pharmaceuticals2013;6:988–1038;3.GustavssonB,etal.ClinColorectalCancer2015;14:1–10; 4.DanenbergPV,etal.CritRevOncolHematol2016;106:118–31;5.OdinE,etal.MolMed2015;21:597–604;6.GustavssonB,etal.PosterpresentationatASCO2018Congress.Posterno.3550(#43);7.WettergrenY,etal.CancerChemotherPharmacol2015;75:37–47;8.Isofol.Pressrelease,May2019.Availableat:https://isofolmedical.com/ news-press/?detail=8DE31DA3DD13C740.LastaccessedSeptember2019;9.CarlssonG,etal.PosterpresentationatESMO2018Congress.Posterno.569P; 10.ClinicalTrials.gov.Availableat:https://clinicaltrials.gov/ct2/show/NCT03750786.LastaccessedSeptember2019.
SUMMARY• IncontrasttofolatescurrentlyapprovedtotreatmCRC,arfolitixorindoesnotrequiremetabolicactivationandmayproducehigherandmoreconsistent
concentrationsof[6R]-MTHFthanthecomparatorleucovorin,whichmayinturnimproveclinicalefficacy• ThisPhaseIIIstudywillcomparetheefficacyoffirst-linearfolitixorinversusleucovorinincombinationwith5-FU,oxaliplatin,andbevacizumabinpatients
with mCRC• TheprimaryendpointwillbeORRandkeysecondaryendpointswillincludePFSandDoR• AtranslationalprogramwillexploretherelationshipbetweenexpressionlevelsofkeygenesinvolvedinfolatemetabolismandtransportinmCRCtumor
biopsies,andtreatmentefficacy• InterimdataareanticipatedinQ32020(Figure 5)
EXPLORATORY ANALYSES• Atranslationalprogramwilldeterminefolatemetabolism-andtransportation-relatedgeneexpressionlevelsinallpatients• Fixed-formalinparaffin-embeddedmCRCtumorsectionsderivedfrombiopsiesobtainedpriortotreatmentinitiationwillbeusedforgeneexpression
analysisviaavalidatedtechniquetobeconductedatacentralaccreditedlaboratoryinGothenburg,Sweden• Levelsofthefollowinggeneswillberetrospectivelyanalyzed:adenosinetriphosphate(ATP)-bindingcassetteC3transporter,methylenetetrahydrofolate
dehydrogenase2,proton-coupledfolatetransporter,serinehydroxymethyltransferase1,peptidylprolyl-isomeraseA,andbeta-actin
5-FU, 5-fluorouracil; CT, computerized tomography; ECOG, Eastern Cooperative Oncology Group; mCRC, metastatic colorectal cancer; MRI, magnetic resonance imaging; PS, performance status.
KEY ELIGIBILITY CRITERIA
Inclusion
• Adults≥18yearsofage• Colorectaladenocarcinomaverifiedbybiopsy • Availabilityofbiopsymaterial,fromtheprimary
tumor or metastasis, allowing for analysis of tumor gene expression
• Non-resectablemCRCplannedforfirst-linetherapywithleucovorin,5-FU,oxaliplatin,andbevacizumab
• Evaluabledisease(viaCTscanorMRI)• ECOGPS0or1• Adequatehematologicfunction • Adequatehepaticfunction • Adequaterenalfunction
Exclusion
• Malignanttumorsotherthancolorectal adenocarcinomas
• <6monthssincelastanti-cancertreatment• Knowndihydropyrimidinedehydrogenasedeficiency• Clinicallysignificantcardiovasculardisease• Central nervous system metastases
Copies of this poster obtained through Quick
Response (QR) Code are for personal use only and may not be reproduced without
permission from ASCO® and the author of this poster.
ASCO-GI Congress 2020. Poster no. TPS268
ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
• Non-resectable mCRC
• Eligible for 5-FU, oxaliplatin, and bevacizumab therapy
• ECOG PS 0 or 1 Stratification factors:• Geographic region• Primary tumor location• Previous neo-adjuvant/ adjuvant treatment
Randomization 1:1
ARFOX: arfolitixorin, 60 mg/m2 IV bolus twice (total 120 mg/m2); 5-FU, 400 mg/m2 IV bolus, 2,400 mg/m2 IV infusion;
oxaliplatin, 85 mg/m2 IV infusion + bevacizumab, 5 mg/kg IV infusion
Interim analysis: first ~330 patients
Patients
n=440
mFOLFOX-6: leucovorin, 400 mg/m2 IV infusion; 5-FU, 400 mg/m2 IV bolus, 2,400 mg/m2 IV infusion;
oxaliplatin, 85 mg/m2 IV infusion+ bevacizumab, 5 mg/kg IV infusion
Disease progression
Disease progression
Primary endpointORR
Key secondary endpointsPFSDoR
Additional secondary endpointsOS
QoLSafety and tolerability
Patients undergoing curative metastasis resection
5-FU, 5-fluorouracil; ARFOX, arfolitixorin, 5-FU, and oxaliplatin; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; IV, intravenous; mCRC, metastatic colorectal cancer; mFOLFOX-6, modified FOLFOX-6 (leucovorin, 5-FU, and oxaliplatin); ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PS, performance status; QoL, quality of life.
Figure 3. Study design and planned analyses
Final analysis (ORR and PFS)
Figure 5. Key study milestones
5-FU metabolite competes to inhibit TS (and DNA synthesis), Arfolitixorin stabilizes 5-FU metabolite to inhibit TS (and block DNA synthesis)
5-FU FdUMP FdUMPTS-substrate
(dUMP)
5-FU displaced due to MTHF shortage
Thymidineshortage
Normalized thymidineavailability
NormalDNA synthesis
Tumor cell survival
Arrested DNA synthesis
Tumor cell death Tumor cell death
ARFOLITIXORIN
Persistent thymidine shortage
Persistent DNA synthesis arrest
5-FU FdUMPTS-substrate
(dUMP)TS-substrate
(dUMP)
TS TS TS
5-FU, 5-fluorouracil; dUMP, deoxyuridine monophosphate; FdUMP, 5-fluorodeoxyuridine monophosphate; MTHF, [6R]-5,10-methylenetetrahydrofolate; TS, thymidylate synthase.
Figure 4. Sites participating in the AGENT study
Figure 2. Multi-step activation of folates
Figure 1. Mechanism of action of arfolitixorin
5-FU, 5-fluorouracil; THF, tetrahydrofolate.
ISO01045_Isofol_AGENT_ENCORE_Clinical_Poster_for_ASCO_Dec_2019_1144x2363_Fa1b.indd 1ISO01045_Isofol_AGENT_ENCORE_Clinical_Poster_for_ASCO_Dec_2019_1144x2363_Fa1b.indd 1 21/01/2020 16:2721/01/2020 16:27